ALISHA FANGMEYER: Open Payments
NPI 1568756609 · SUPERIOR, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$291 in 17 payments from 8 companies in 2025. Trend: 2023 $538 · 2024 $378 · 2025 $291
Food & beverage: $291
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $70 |
| Gilead Sciences, Inc. | 4 | $68 |
| Novo Nordisk Inc | 3 | $47 |
| ABBVIE INC. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Amgen Inc. | 1 | $16 |
| Janssen Pharmaceuticals, Inc | 1 | $14 |
Products named: REXULTI, Ozempic, VRAYLAR, CAPLYTA, Auvelity, EVENITY, Epclusa, SPRAVATO.
Industry payments across NE — which companies pay providers there.
